8-K/A: Progyny Reports 10.6% Revenue Growth in Q4 2024, Issues Positive Guidance for 2025

Progyny, Inc. announced its Q4 2024 financial results, reporting a 10.6% increase in quarterly revenue to $298.4 million and issuing financial guidance for 2025, projecting continued revenue growth.

Summary

• Progyny, Inc. reported its financial results for the fourth quarter and full year 2024.
• Q4 revenue increased by 10.6% to $298.4 million compared to $269.9 million in Q4 2023.
• Full-year revenue grew by 7.2% to $1,167.2 million compared to $1,088.6 million in the prior year.
• Net income for Q4 was $10.5 million, or $0.12 per diluted share, compared to $13.5 million, or $0.13 per diluted share, in Q4 2023.
• Full-year net income was $54.3 million, or $0.57 per diluted share, compared to $62.0 million, or $0.62 per diluted share, in the prior year.
• Adjusted EBITDA for Q4 increased by 10% to $47.5 million compared to $43.2 million in Q4 2023.
• Full-year Adjusted EBITDA increased by 6.2% to $198.8 million compared to $187.1 million in the prior year.
• The company had 473 clients as of December 31, 2024, compared to 392 clients as of December 31, 2023.
• Progyny is projecting full-year 2025 revenue to be between $1.175 billion and $1.225 billion, representing growth of 1% to 5%.
• The company anticipates having more than 530 clients, representing an estimated 6.7 million covered lives in 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company experienced revenue growth and returned capital to shareholders, net income decreased, and the guidance for 2025 reflects some uncertainty. The management's comments are optimistic, but the financial results present a mixed picture.

Positives

• Progyny experienced revenue growth in both Q4 and full-year 2024.
• The company increased its client base from 392 to 473 in 2024.
• Progyny generated $179 million in cash flow from operations in 2024.
• The company returned $300 million to shareholders through share repurchase programs.
• Progyny has a strong balance sheet with $228.0 million in cash and marketable securities and no debt.
• The company is projecting continued revenue growth in 2025.

Negatives

• Net income decreased in both Q4 and full-year 2024 due to a higher provision for income taxes.
• Adjusted EBITDA margin decreased slightly from 17.2% to 17.0% for the full year.
• One large client did not renew its services agreement for 2025.
• Net cash provided by operating activities decreased in 2024 compared to the prior year.

Risks

• The company acknowledges potential variability in member engagement in 2025.
• The loss of a large client could impact future revenue.
• The company's future performance depends on its ability to attract and retain clients.
• Changes in the healthcare and benefits industries could affect Progyny's business.

Future Outlook

Progyny projects full-year 2025 revenue to be between $1.175 billion and $1.225 billion, reflecting growth of 1% to 5%. Net income is projected to be $45.0 million to $53.9 million, and Adjusted EBITDA is projected to be $188.0 million to $201.0 million.

Management Comments

• Pete Anevski, CEO, stated that 2024 ended on a strong note with continued improvement in member engagement.
• Pete Anevski, CEO, mentioned that member engagement is trending towards historical levels as 2025 begins.
• Mark Livingston, CFO, said that 2024 was a strong year for Progyny, with record levels of revenue and Adjusted EBITDA.

Industry Context

Progyny operates in the growing fertility and family building benefits market. The company's focus on value-based care and comprehensive solutions positions it to capitalize on the increasing demand for these services from employers and health plans.

Comparison to Industry Standards

• Progyny's revenue growth of 7.2% for the full year 2024 is comparable to other companies in the healthcare benefits space, such as Accolade, Inc. which reported revenue growth of 12% in their most recent fiscal year.
• Progyny's Adjusted EBITDA margin of 17.0% is in line with industry standards for companies providing specialized healthcare benefits.
• Compared to Teladoc Health, which focuses on virtual care, Progyny's focus on fertility and family building provides a more niche offering with potentially higher engagement rates.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program.
• Employees will continue to be part of a growing company.
• Clients will have access to Progyny's fertility and family building benefits solutions.
• Patients will receive support and access to fertility specialists.

Next Steps

• Progyny will continue to focus on client acquisition and expanding its covered lives.
• The company will monitor member engagement and adjust its strategies as needed.
• Progyny will execute its share repurchase program.

Key Dates